2022
Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation
Noseworthy PA, Van Houten HK, Krumholz HM, Kent DM, Abraham NS, Graff‐Radford J, Alkhouli M, Henk HJ, Shah ND, Gersh BJ, Friedman PA, Holmes DR, Yao X. Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation. Journal Of The American Heart Association 2022, 11: e027001. PMID: 36172961, PMCID: PMC9673739, DOI: 10.1161/jaha.121.027001.Peer-Reviewed Original ResearchConceptsComposite end pointAtrial appendage occlusionOral anticoagulantsAtrial fibrillationLower riskMajor bleedingSystemic embolismIntracranial bleedingAppendage occlusionNon-Vitamin K Antagonist Oral AnticoagulantsIschemic stroke/systemic embolismK Antagonist Oral AnticoagulantsPrimary composite end pointPropensity score overlap weightingStroke/systemic embolismEnd pointHigh bleeding riskSignificant differencesAntithrombotic regimensBleeding riskCause mortalityBaseline characteristicsComposite outcomeIschemic strokeSecondary outcomes
2020
Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic
Jasne AS, Chojecka P, Maran I, Mageid R, Eldokmak M, Zhang Q, Nystrom K, Vlieks K, Askenase M, Petersen N, Falcone GJ, Wira CR, Lleva P, Zeevi N, Narula R, Amin H, Navaratnam D, Loomis C, Hwang DY, Schindler J, Hebert R, Matouk C, Krumholz HM, Spudich S, Sheth KN, Sansing LH, Sharma R. Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic. Stroke 2020, 51: 2664-2673. PMID: 32755347, PMCID: PMC7446978, DOI: 10.1161/str.0000000000000347.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBetacoronavirusBrain IschemiaCohort StudiesComorbidityConnecticutCoronary Artery DiseaseCoronavirus InfectionsCOVID-19DyslipidemiasEmergency Medical ServicesEthnicityFemaleHumansHypertensionIncomeInsurance, HealthIntracranial HemorrhagesMaleMedically UninsuredMiddle AgedOutcome and Process Assessment, Health CarePandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2Severity of Illness IndexStrokeSubstance-Related DisordersTelemedicineThrombectomyThrombolytic TherapyTime-to-TreatmentConceptsComprehensive stroke centerStroke codePatient characteristicsStroke severityStroke code patientsHistory of hypertensionStroke-like symptomsCoronary artery diseaseCoronavirus disease 2019 (COVID-19) pandemicPatient-level dataLower median household incomePublic health initiativesDisease 2019 pandemicCOVID-19 pandemicRace/ethnicityCode patientsHospital presentationPublic health insuranceRankin ScaleStroke centersArtery diseaseReperfusion timeStroke symptomsEarly outcomesConnecticut hospitals
2016
Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation
Dodson JA, Petrone A, Gagnon DR, Tinetti ME, Krumholz HM, Gaziano JM. Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation. JAMA Cardiology 2016, 1: 65. PMID: 27437657, PMCID: PMC5600874, DOI: 10.1001/jamacardio.2015.0345.Peer-Reviewed Original ResearchConceptsTraumatic intracranial bleedingIntracranial bleedingInternational normalized ratioIschemic strokeAtrial fibrillationIncidence rateAnticonvulsant useWarfarin therapyNormalized ratioRisk factorsOlder adultsVeterans AffairsCox proportional hazards regressionVA electronic medical recordsMean patient agePatients 75 yearsRetrospective cohort studyClinical Modification codesCoronary artery diseaseProportional hazards regressionService claims dataVA administrative dataSignificant predictorsHealth care professionalsElectronic medical records
2015
Predictors of warfarin‐associated adverse events in hospitalized patients: Opportunities to prevent patient harm
Metersky ML, Eldridge N, Wang Y, Jaser L, Bona R, Eckenrode S, Bakullari A, Andrawis M, Classen D, Krumholz HM. Predictors of warfarin‐associated adverse events in hospitalized patients: Opportunities to prevent patient harm. Journal Of Hospital Medicine 2015, 11: 276-282. PMID: 26662851, DOI: 10.1002/jhm.2528.Peer-Reviewed Original ResearchConceptsAdverse eventsWarfarin-related adverse eventsHospitalized patientsOdds ratioINR monitoringPneumonia patientsINR measurementsFrequent INR monitoringPredictors of warfarinRetrospective cohort studyAcute cardiac diseaseAcute care hospitalsFrequency of warfarinCohort studyCare hospitalSurgical patientsCardiac patientsCardiac diseasePatientsPatient harmWarfarinSignificant associationINRMore daysMonitoring System data
2004
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB, Investigators A. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). The American Journal Of Cardiology 2004, 94: 279-283. PMID: 15276088, DOI: 10.1016/j.amjcard.2004.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPartial Thromboplastin TimeProbabilityRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival RateTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsWeight-adjusted heparinST-elevation myocardial infarctionASSENT-3Myocardial infarctionASSENT-2Major bleedingIntracranial hemorrhageSmall doseFull-dose tenecteplaseLess major bleedingNew thrombolytic regimenOutcomes of patientsAcute myocardial infarctionPartial thromboplastin timeSimilar ratesRefractory ischemiaThrombolytic regimenRecurrent infarctionBaseline characteristicsHemorrhagic complicationsUnfractionated heparinThromboplastin timePatientsInfarctionTenecteplase
2000
Intracranial Hemorrhage Associated With Thrombolytic Therapy for Elderly Patients With Acute Myocardial Infarction
Brass L, Lichtman J, Wang Y, Gurwitz J, Radford M, Krumholz H. Intracranial Hemorrhage Associated With Thrombolytic Therapy for Elderly Patients With Acute Myocardial Infarction. Stroke 2000, 31: 1802-1811. PMID: 10926938, DOI: 10.1161/01.str.31.8.1802.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombolytic therapyIntracranial hemorrhageMyocardial infarctionElderly patientsIntracranial Hemorrhage AssociatedRetrospective cohort studyRisk stratification scaleMain outcome measuresAcute care hospitalsTissue plasminogen activatorExcessive anticoagulationPrior strokeCohort studyOlder patientsBlood pressureHemorrhage AssociatedIndependent predictorsMedical chartsSerious complicationsMedian weightAlternate therapyBlack racePrincipal diagnosisMedicare patients